AP NEWS

Investigation Report on China’s Glimepiride Market, 2018-2022 - ResearchAndMarkets.com

December 4, 2018

DUBLIN--(BUSINESS WIRE)--Dec 4, 2018--The “Investigation Report on China’s Glimepiride Market, 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

Glimepiride is a third-generation sulfonylurea insulin secretagogue. Sanofi’s brand-name drug (trade name: Amaryl) have been marketed in many countries after it was approved by the FDA (U.S. Food and Drug Administration) on Nov. 30, 1995.

Glimepiride is the sulfonylurea hypoglycemic agent that has best clinical effectiveness as well as the first sulfonylurea approved by the FDA to be used together with insulin. It does much better in sensitizing and simulating insulin than other sulfonylureas. For type 2 diabetic patients with insulin resistance (reduced glucose utilization in peripheral tissues), Glimepiride reduces blood glucose by sensitizing and simulating insulin. For type 2 diabetic patients with insulin secretion dysfunction, Glimepiride reduces blood glucose by stimulating insulin secretion.

According to the author, with the development of China’s economy, the rise of urbanization level, and the aging of population, the life style of Chinese people is changing, which increases the obese population and the incidence of diabetes in China. It is estimated that the number of type 2 diabetic patients in China had surpassed 1 million by the end of 2017, and is growing by 1.5 million to 2 million every year. The growing number of diabetics in China promotes the growth of the antidiabetic drug market.

According to the author, generic products have sprung up one after another since 2004 when Sanofi (Beijing) Pharmaceutical Co., Ltd. launched Amaryl in China. In 2017, the market size of Glimepiride in China was about CNY 302 million. There are over 10 Glimepiride manufacturers in China.

The major market players include Sanofi (Beijing) Pharmaceutical Co., Ltd., Jiangsu Wanbang Biopharmaceuticals Co., Ltd., CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., and Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. By sales value, in 2017, Sanofi (Beijing) Pharmaceutical Co., Ltd.’s Amaryl captured more than 80% share of China’s Glimepiride market.

Key Topics Covered:

1. Relevant Concepts of Glimepiride

2. Sales of Glimepiride in China, 2013-2017

3. Analysis on Major Glimepiride Manufacturers in China, 2013-2017

4. Prices of Glimepiride in China, 2017-2018

5. Prospect of China’s Glimepiride Market, 2018-2022

For more information about this report visit https://www.researchandmarkets.com/research/2jnh3p/investigation?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181204005988/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs,Diabetes Drugs

KEYWORD: ASIA PACIFIC CHINA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL DIABETES

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/04/2018 02:41 PM/DISC: 12/04/2018 02:41 PM

http://www.businesswire.com/news/home/20181204005988/en

AP RADIO
Update hourly